

# SAFETY DATA SHEET



## Montelukast Tablet Formulation



Version 3.2      Revision Date: 2024/04/06      SDS Number: 23076-00024      Date of last issue: 2023/09/26  
Date of first issue: 2014/10/17

---

### 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Montelukast Tablet Formulation

#### Manufacturer or supplier's details

Company : Organon & Co.

Address : JL Raya Pandaan KM. 48  
Pandaan, Jawa Timur - Indonesia

Telephone : +1-551-430-6000

Emergency telephone number : +1-215-631-6999

E-mail address : EHSSTEWARD@organon.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

---

### 2. HAZARDS IDENTIFICATION

#### GHS Classification

Not a hazardous substance or mixture.

#### GHS label elements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required

#### Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

---

### 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

#### Components

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 30 -< 60
Montelukast	151767-02-1	< 10
Magnesium stearate	557-04-0	< 10
Titanium dioxide	13463-67-7	< 1

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
3.2	2024/04/06	23076-00024	Date of first issue: 2014/10/17

---

**4. FIRST AID MEASURES**

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : Wash with water and soap.  
Get medical attention if symptoms occur.
- In case of eye contact : If in eyes, rinse well with water.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention if symptoms occur.  
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Contact with dust can cause mechanical irritation or drying of the skin.  
Dust contact with the eyes can lead to mechanical irritation.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.
- 

**5. FIREFIGHTING MEASURES**

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides  
Metal oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.
- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.
- 

**6. ACCIDENTAL RELEASE MEASURES**

- Personal precautions, protective equipment and emergency measures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal pro-

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
3.2	2024/04/06	23076-00024	Date of first issue: 2014/10/17

---

- gency procedures : tective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

**7. HANDLING AND STORAGE**

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe dust.  
Do not swallow.  
Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labelled containers.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

## Montelukast Tablet Formulation

Version 3.2      Revision Date: 2024/04/06      SDS Number: 23076-00024      Date of last issue: 2023/09/26  
 Date of first issue: 2014/10/17

## 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	NAB	10 mg/m <sup>3</sup>	ID OEL
		TWA	10 mg/m <sup>3</sup>	ACGIH
Montelukast	151767-02-1	TWA	40 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	400 µg/100 cm <sup>2</sup>	Internal
Magnesium stearate	557-04-0	NAB	10 mg/m <sup>3</sup>	ID OEL
Further information: Not classified as carcinogenic to humans. Not enough data to classify these materials as carcinogenic to humans or animals				
		TWA (Inhalable particulate matter)	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable particulate matter)	3 mg/m <sup>3</sup>	ACGIH
Titanium dioxide	13463-67-7	NAB	10 mg/m <sup>3</sup>	ID OEL
Further information: Not classified as carcinogenic to humans. Not enough data to classify these materials as carcinogenic to humans or animals				

**Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
Minimize open handling.

**Personal protective equipment**

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
3.2	2024/04/06	23076-00024	Date of first issue: 2014/10/17

---

Skin and body protection : aerosols.  
 : Work uniform or laboratory coat.  
 Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
 Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
 When using do not eat, drink or smoke.  
 Wash contaminated clothing before re-use.  
 The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

---

**9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance : tablet  
 Colour : coloured  
 Odour : odourless  
 Odour Threshold : No data available  
 pH : No data available  
 Melting point/freezing point : No data available  
 Initial boiling point and boiling range : No data available  
 Flash point : Not applicable  
 Evaporation rate : No data available  
 Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.  
 Flammability (liquids) : No data available  
 Upper explosion limit / Upper flammability limit : No data available  
 Lower explosion limit / Lower flammability limit : No data available  
 Vapour pressure : No data available  
 Relative vapour density : No data available

# SAFETY DATA SHEET



## Montelukast Tablet Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
3.2	2024/04/06	23076-00024	Date of first issue: 2014/10/17

---

Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n- octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics Particle size	:	No data available

---

### 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reac- tions	:	May form explosive dust-air mixture during processing, han- dling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

---

### 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
---	---	--

#### Acute toxicity

Not classified based on available information.

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
3.2	2024/04/06	23076-00024	2023/09/26
			Date of first issue: 2014/10/17

---

**Components:****Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

**Montelukast:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
LD50 (Mouse): > 5,000 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

**Magnesium stearate:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 423  
Assessment: The substance or mixture has no acute oral toxicity  
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg  
Remarks: Based on data from similar materials

**Titanium dioxide:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 6.82 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Assessment: The substance or mixture has no acute inhalation toxicity

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Montelukast:**

Species : Rabbit  
Result : Mild skin irritation

**Magnesium stearate:**

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
3.2	2024/04/06	23076-00024	Date of first issue: 2014/10/17

---

Species : Rabbit  
Result : No skin irritation  
Remarks : Based on data from similar materials

### **Titanium dioxide:**

Species : Rabbit  
Result : No skin irritation

### **Serious eye damage/eye irritation**

Not classified based on available information.

### **Components:**

#### **Montelukast:**

Species : Rabbit  
Result : Severe irritation

#### **Magnesium stearate:**

Species : Rabbit  
Result : No eye irritation  
Remarks : Based on data from similar materials

#### **Titanium dioxide:**

Species : Rabbit  
Result : No eye irritation

### **Respiratory or skin sensitisation**

#### **Skin sensitisation**

Not classified based on available information.

#### **Respiratory sensitisation**

Not classified based on available information.

### **Components:**

#### **Montelukast:**

Remarks : No data available

#### **Magnesium stearate:**

Test Type : Maximisation Test  
Exposure routes : Skin contact  
Species : Guinea pig  
Method : OECD Test Guideline 406  
Result : negative  
Remarks : Based on data from similar materials



## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
3.2	2024/04/06	23076-00024	Date of first issue: 2014/10/17

---

**Titanium dioxide:**

Test Type	: Local lymph node assay (LLNA)
Exposure routes	: Skin contact
Species	: Mouse
Result	: negative

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Cellulose:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	Test Type: In vitro mammalian cell gene mutation test Result: negative
Genotoxicity in vivo	: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Ingestion Result: negative

**Montelukast:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	Test Type: In vitro mammalian cell gene mutation test Test system: Chinese hamster fibroblasts Result: negative
	Test Type: Chromosomal aberration Test system: Chinese hamster ovary cells Result: negative
	Test Type: Alkaline elution assay Test system: rat hepatocytes Result: negative
Genotoxicity in vivo	: Test Type: Chromosomal aberration Species: Mouse Cell type: Bone marrow Application Route: Oral Result: negative

**Magnesium stearate:**

Genotoxicity in vitro	: Test Type: In vitro mammalian cell gene mutation test Result: negative Remarks: Based on data from similar materials
-----------------------	--

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
3.2	2024/04/06	23076-00024	Date of first issue: 2014/10/17

---

Test Type: Chromosome aberration test in vitro  
 Method: OECD Test Guideline 473  
 Result: negative  
 Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)  
 Result: negative  
 Remarks: Based on data from similar materials

**Titanium dioxide:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
 Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test  
 Species: Mouse  
 Result: negative

**Carcinogenicity**

Not classified based on available information.

**Components:****Cellulose:**

Species : Rat  
 Application Route : Ingestion  
 Exposure time : 72 weeks  
 Result : negative

**Montelukast:**

Species : Rat  
 Application Route : Oral  
 Exposure time : 2 Years  
 Result : negative

Species : Mouse  
 Application Route : Oral  
 Exposure time : 92 weeks  
 Result : negative

**Titanium dioxide:**

Species : Rat  
 Application Route : inhalation (dust/mist/fume)  
 Exposure time : 2 Years  
 Method : OECD Test Guideline 453  
 Result : positive  
 Remarks : The mechanism or mode of action may not be relevant in humans.

Carcinogenicity - Assess- : Limited evidence of carcinogenicity in inhalation studies with

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
3.2	2024/04/06	23076-00024	Date of first issue: 2014/10/17

---

ment animals.

**Reproductive toxicity**

Not classified based on available information.

**Components:****Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative

**Montelukast:**

Effects on fertility : Test Type: Fertility  
Species: Rat, male  
Application Route: Oral  
Fertility: NOAEL: 800 mg/kg body weight  
Result: Animal testing did not show any effects on fertility.

Test Type: Fertility  
Species: Rat, female  
Application Route: Oral  
Fertility: LOAEL: 200 mg/kg body weight  
Symptoms: Reduced fertility

Test Type: Fertility  
Species: Rat, female  
Application Route: Oral  
Fertility: NOAEL: 100 mg/kg body weight  
Symptoms: Reduced fertility

**Magnesium stearate:**

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 422  
Result: negative  
Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
3.2	2024/04/06	23076-00024	Date of first issue: 2014/10/17

---

**STOT - single exposure**

Not classified based on available information.

**STOT - repeated exposure**

Not classified based on available information.

**Repeated dose toxicity****Components:****Cellulose:**

Species	: Rat
NOAEL	: $\geq 9,000$ mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days

**Montelukast:**

Species	: Monkey, male and female
NOAEL	: 150 - 300 mg/kg
Application Route	: Oral
Exposure time	: 53 Weeks
Remarks	: No significant adverse effects were reported

Species	: Rat
NOAEL	: 50 mg/kg
Application Route	: Oral
Exposure time	: 53 Weeks
Remarks	: No significant adverse effects were reported

Species	: Mouse
NOAEL	: 50 mg/kg
Application Route	: Oral
Exposure time	: 14 Weeks
Remarks	: No significant adverse effects were reported

**Magnesium stearate:**

Species	: Rat
NOAEL	: $> 100$ mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days
Remarks	: Based on data from similar materials

**Titanium dioxide:**

Species	: Rat
NOAEL	: 24,000 mg/kg
Application Route	: Ingestion
Exposure time	: 28 Days

Species	: Rat
---------	-------

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
3.2	2024/04/06	23076-00024	Date of first issue: 2014/10/17

---

NOAEL : 10 mg/m<sup>3</sup>  
 Application Route : inhalation (dust/mist/fume)  
 Exposure time : 2 yr

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Montelukast:**

Skin contact : Remarks: May irritate skin.  
 Eye contact : Symptoms: Severe irritation  
 Ingestion : Symptoms: upper respiratory tract infection, pharyngitis,  
 Headache, Cough, Abdominal pain, Diarrhoea, Fever

---

**12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Cellulose:**

Toxicity to fish : LC50 (*Oryzias latipes* (Japanese medaka)): > 100 mg/l  
 Exposure time: 48 h  
 Remarks: Based on data from similar materials

**Montelukast:**

Toxicity to fish : LC50 (*Pimephales promelas* (fathead minnow)): > 0.0778 mg/l  
 Exposure time: 96 h  
 Method: OECD Test Guideline 203  
 Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other : EC50 (*Daphnia magna* (Water flea)): > 0.0675 mg/l  
 aquatic invertebrates : Exposure time: 48 h  
 Method: OECD Test Guideline 202  
 Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic : NOEC (*Pseudokirchneriella subcapitata* (green algae)): 100  
 plants : mg/l  
 Exposure time: 72 h  
 Method: OECD Test Guideline 201  
 Remarks: No toxicity at the limit of solubility

EC50 (*Pseudokirchneriella subcapitata* (green algae)): > 100  
 mg/l  
 Exposure time: 72 h  
 Method: OECD Test Guideline 201  
 Remarks: No toxicity at the limit of solubility

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
3.2	2024/04/06	23076-00024	Date of first issue: 2014/10/17

---

- Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.073 mg/l  
 Exposure time: 32 d  
 Method: OECD Test Guideline 210  
 Remarks: No toxicity at the limit of solubility
- NOEC (Cyprinodon variegatus (sheepshead minnow)): 0.0816 mg/l  
 Exposure time: 7 d  
 Remarks: No toxicity at the limit of solubility
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.23 mg/l  
 Exposure time: 21 d  
 Remarks: No toxicity at the limit of solubility
- Toxicity to microorganisms : EC50: > 100 mg/l  
 Exposure time: 3 h  
 Test Type: Respiration inhibition  
 Method: OECD Test Guideline 209  
 Remarks: No toxicity at the limit of solubility

**Magnesium stearate:**

- Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l  
 Exposure time: 48 h  
 Method: DIN 38412  
 Remarks: Based on data from similar materials
- Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l  
 Exposure time: 47 h  
 Test substance: Water Accommodated Fraction  
 Method: Directive 67/548/EEC, Annex V, C.2.  
 Remarks: Based on data from similar materials  
 No toxicity at the limit of solubility
- Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
 Exposure time: 72 h  
 Test substance: Water Accommodated Fraction  
 Method: OECD Test Guideline 201  
 Remarks: Based on data from similar materials  
 No toxicity at the limit of solubility
- NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
 Exposure time: 72 h  
 Test substance: Water Accommodated Fraction  
 Method: OECD Test Guideline 201  
 Remarks: Based on data from similar materials
- Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l  
 Exposure time: 16 h  
 Test substance: Water Accommodated Fraction  
 Remarks: Based on data from similar materials

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
3.2	2024/04/06	23076-00024	Date of first issue: 2014/10/17

---

**Titanium dioxide:**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l  
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50 (Skeletonema costatum (marine diatom)): > 10,000 mg/l  
Exposure time: 72 h

Toxicity to microorganisms : EC50: > 1,000 mg/l  
Exposure time: 3 h  
Method: OECD Test Guideline 209

**Persistence and degradability****Components:****Cellulose:**

Biodegradability : Result: Readily biodegradable.

**Montelukast:**

Biodegradability : Result: not rapidly degradable  
Biodegradation: 0 %  
Exposure time: 28 d

Stability in water : Hydrolysis: 50 %(21.7 h)

**Magnesium stearate:**

Biodegradability : Result: Not biodegradable  
Remarks: Based on data from similar materials

**Bioaccumulative potential****Components:****Montelukast:**

Partition coefficient: n-octanol/water : log Pow: > 4.3

**Magnesium stearate:**

Partition coefficient: n-octanol/water : log Pow: > 4

**Mobility in soil**

No data available

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
3.2	2024/04/06	23076-00024	Date of first issue: 2014/10/17

---

### Other adverse effects

No data available

---

## 13. DISPOSAL CONSIDERATIONS

### Disposal methods

Waste from residues	:	Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

---

## 14. TRANSPORT INFORMATION

### International Regulations

#### UNRTDG

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Environmentally hazardous	:	no

#### IATA-DGR

UN/ID No.	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Packing instruction (cargo aircraft)	:	Not applicable
Packing instruction (passenger aircraft)	:	Not applicable

#### IMDG-Code

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
EmS Code	:	Not applicable
Marine pollutant	:	Not applicable

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### Special precautions for user

Not applicable

---



## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
3.2	2024/04/06	23076-00024	Date of first issue: 2014/10/17

---

---

**15. REGULATORY INFORMATION**

**Safety, health and environmental regulations/legislation specific for the substance or mixture**

**Minister of Industry Regulation No. 23/M-IND/PER/4/2013 concerning the Revision of Minister of Industry Regulation No. 87/M-IND/PER/9/2009 concerning Globally Harmonized System of Classification and Labelling of Chemicals.**

**Regulation of the Minister of Health No. 472 of 1996 on the Safeguarding of Substances Hazardous to Health**

Hazardous substances that must be registered : Not applicable

**Government Regulation No. 74 of 2001 on the Management of Hazardous and Toxic Substances**

Hazardous substances approved for use : Not applicable

Prohibited substances : Not applicable

Restricted substances : Not applicable

**Regulation of the Ministry of Trade No. 7 of 2022 on Distribution and Control of Hazardous Materials**

Type of hazardous materials subject to distribution and control, Annex I : Not applicable

Type of hazardous materials subject to distribution and control, Annex II : Not applicable

**The components of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

---

**16. OTHER INFORMATION**

Revision Date : 2024/04/06

**Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : yyyy/mm/dd

**Full text of other abbreviations**

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

# SAFETY DATA SHEET



## Montelukast Tablet Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
3.2	2024/04/06	23076-00024	Date of first issue: 2014/10/17

---

ID OEL : Indonesia. Occupational Exposure Limits

ACGIH / TWA : 8-hour, time-weighted average

ID OEL / NAB : Long term exposure limit

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ID / EN